150 related articles for article (PubMed ID: 34713370)
21. ASO Author Reflections: Pathologic Classification of Pseudomyxoma Peritonei.
Baratti D
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):844-845. PubMed ID: 30324483
[No Abstract] [Full Text] [Related]
22. ASO Author Reflections: Long-Term Survival Is Feasible After Complete CRS/HIPEC for Biphasic Peritoneal Mesothelioma.
Chouliaras K; Votanopoulos KI
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):770-771. PubMed ID: 30421064
[No Abstract] [Full Text] [Related]
23. ASO Author Reflections: Cytoreductive Surgery for Colorectal Peritoneal Metastases-Is It Time to Audit Our Results?
García-Fadrique A
Ann Surg Oncol; 2022 Jan; 29(1):203-204. PubMed ID: 34435299
[No Abstract] [Full Text] [Related]
24. ASO Author Reflections: Is There Still a Role for Intraperitoneal Oxaliplatin for Colorectal Peritoneal Metastases?
Taibi A; Hübner M; Eveno C; Dumont F; Glehen O; Sgarbura O
Ann Surg Oncol; 2022 Aug; 29(8):5252-5253. PubMed ID: 35355127
[No Abstract] [Full Text] [Related]
25. ASO Author Reflections: Repeated Intraperitoneal Paclitaxel with Systemic Chemotherapy as the First-Line Treatment for Peritoneal Malignancy.
Kitayama J; Saito S; Yamaguchi H; Lefor AK; Ishigami H; Sata N
Ann Surg Oncol; 2021 Jul; 28(7):3871-3872. PubMed ID: 33432487
[No Abstract] [Full Text] [Related]
26. ASO Author Reflections: Can Patient Selection for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy be Improved?
Graf W; Birgisson H
Ann Surg Oncol; 2020 Jan; 27(1):301-302. PubMed ID: 31520210
[No Abstract] [Full Text] [Related]
27. ASO Author Reflections: Cost Effectiveness of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Lee ZJ; Teo CCM
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):757-758. PubMed ID: 30374919
[No Abstract] [Full Text] [Related]
28. ASO Author Reflections: The Effect of Bowel Resection During Cytoreductive Surgery/Hyperthermic Intraperitoneal Chemotherapy on Bowel-Related Quality of Life.
Bayat Z; Govindarajan A
Ann Surg Oncol; 2020 Jan; 27(1):132-133. PubMed ID: 31602581
[No Abstract] [Full Text] [Related]
29. ASO Author Reflections: Pleuropulmonary Recurrence Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Appendiceal Pseudomyxoma Peritonei.
Beane JD; Choudry HA
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):581-582. PubMed ID: 30919225
[No Abstract] [Full Text] [Related]
30. ASO Author Reflections: Cisplatin- and Adrenaline-Based Intraperitoneal Chemotherapy Protocol for Ovarian Peritoneal Carcinosis: New Perspectives?
Paquette B
Ann Surg Oncol; 2022 May; 29(5):3335-3336. PubMed ID: 35072865
[No Abstract] [Full Text] [Related]
31. ASO Author Reflections: If Once Is Good, Is Twice Just as Good? A critical evaluation of Repeat CRS-HIPEC for Colorectal Peritoneal Metastases.
Laks S; Adileh M; Ben-Yaacov A; Nissan A
Ann Surg Oncol; 2021 Sep; 28(9):5339-5340. PubMed ID: 33604829
[No Abstract] [Full Text] [Related]
32. ASO Author Reflections: Molecular Profiling Can Provide Personalized Clinical Guidance in the Management of Peritoneal Malignancies.
Moaven O; Miller LD; Levine EA
Ann Surg Oncol; 2020 Dec; 27(13):5024-5025. PubMed ID: 32749622
[No Abstract] [Full Text] [Related]
33. ASO Author Reflections: Evaluating Conversion of Low-Grade to High-Grade Appendiceal Neoplasms for Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
Mangieri CW; Levine EA
Ann Surg Oncol; 2022 Jan; 29(1):212-213. PubMed ID: 34467501
[No Abstract] [Full Text] [Related]
34. ASO Author Reflections: Challenges in the Management of Bowel Obstruction after Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy.
Mor E; Laks S; Nissan A; Adileh M
Ann Surg Oncol; 2022 Dec; 29(13):8580-8581. PubMed ID: 36018523
[No Abstract] [Full Text] [Related]
35. Defining and Refining the Role for Surgery and Intraperitoneal Chemotherapy in the Treatment of Peritoneal Surface Malignancies.
Choudry MH; Bartlett DL; Alexander HR; Turaga KK
Ann Surg Oncol; 2020 Jan; 27(1):73-75. PubMed ID: 31646448
[No Abstract] [Full Text] [Related]
36. ASO Author Reflections: Delayed Occurrence and Postoperative Risks of Mitomycin-C-Induced Neutropenia After Hyperthermic Intraperitoneal Chemotherapy.
Park EJ; Lee SJ; Baik SH
Ann Surg Oncol; 2022 Mar; 29(3):2087-2088. PubMed ID: 34689262
[No Abstract] [Full Text] [Related]
37. ASO Author Reflections: Fragmented Care in Patients with Peritoneal Metastases.
Vierra M; Bansal VV; Shergill A; Turaga KK; Eng OS
Ann Surg Oncol; 2024 Jan; 31(1):655-656. PubMed ID: 37803088
[No Abstract] [Full Text] [Related]
38. The Role of HIPEC in Gastrointestinal Malignancies: Controversies and Conclusions.
McRee AJ; O'Neil BH
Oncology (Williston Park); 2015 Jul; 29(7):523-4, C3. PubMed ID: 26178341
[No Abstract] [Full Text] [Related]
39. ASO Author Reflections: Prognosticating the Treatment Outcome for Primary Peritoneal Surface Malignancy: Time for an Overhaul of Scoring Systems?
Ihemelandu C
Ann Surg Oncol; 2023 Mar; 30(3):1838-1839. PubMed ID: 36629992
[No Abstract] [Full Text] [Related]
40. ASO Author Reflections: Contemporary Management Trends in Malignant Peritoneal Mesothelioma.
Calthorpe L; Alseidi A; Adam MA
Ann Surg Oncol; 2023 Aug; 30(8):5130. PubMed ID: 37142837
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
